Search

everythinglearnresearchcommunity

for

Search:↓

Treprostinil, a drug, can delay wound healing in healthy cells but doesn't affect diabetic foot ulcer cells, suggesting further research could help understand its role in treating these ulcers.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Tofacitinib treatment for hair loss may worsen acne.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Somatic BHD mutations are rare in Japanese renal tumors.

Tofacitinib, a hair regrowth treatment, may worsen acne.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

JAK inhibitors are effective for long-term management of alopecia areata.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

A new compound shows promise as a topical treatment for hair loss.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.